Athera signs distribution agreement in Scandinavia
(Thomson Reuters ONE) -
Press release
STOCKHOLM, Sweden - August 27, 2010. Athera Biotechnologies and Electra-Box
Diagnostica, announced today that they have signed an agreement for distribution
of "CVDefine" kit. CVDefine measures a new biomarker in blood, a specific
anti-body, that has been linked to increased risk for cardiovascular disease.
Athera Biotechnologies is part of the Karolinska Development portfolio.
Carina Schmidt, VD i Athera:
"This is an important step in the broader commercialization of CVDefine.
Together with Electra-Box we will now be able to expand our contacs with leading
clinial scientist in the cardiovascular field and increase the exposure of our
trademark. We look forward to be able to work with the experienced Electra-Box
team."
Peter Blom, responsible for clinical chemistry in Electra-Box
Diagnostica:
"We are very excited about the opportunities this agreement present. This will
allow us to offer a new CVD biomarker to customers in Scandinavia. Since
CVDefine® may add important and independent information in cardiovascular risk
assessment; we believe there is a lot of interest from scientist in the field to
generate further clinical research data".
High levels of IgM antibodies against phosphorylcholine (anti-PC) have been
shown to be cardio-protective. Low levels of anti-PC are known to be involved in
atherosclerosis development and increased risk for acute cardiovascular events,
like stroke and myocardial infarction. Athera is investigating the possibilities
to develop new immunological therapies to prevent secondary cardiovascular
events and to identify the patients who benefit most from this treatment with
CVDefine, and consequently contribute to better care after acute heart disease.
For additional information, please contact:
Carina Schmidt, CEO Athera Biotechnologies AB
Phone: +4670-552 5115
E-mailt: c.schmidt(at)athera.se
TO THE EDITORS
About Athera Biotechnologies AB (publ)
Athera has a unique and in-depth understanding of the immunological components
in atherosclerosis, the inflammatory process leading to cardiovascular disease
(CVD). The company currently has two biopharmaceutical product candidates aimed
at treating patients with acute heart conditions and a biomarker linked to the
therapeutic approach. Athera is part of the Karolinska Development AB (publ)
portfolio.www.athera.se
About CVDefine
CVDefine® is a diagnostic test measuring IgM anti-bodies against
phosphorylcholine (anti-PC). Low levels of anti-PC indicate a risk for future
development of cardiovascular disease (CVD). CVDefine® is an ELISA kit for early
detection of increased cardiovascular risk due to atherosclerosis and vascular
inflammation.
About Karolinska Development (publ)
Karolinska Development manages one of the largest portfolios of life science
companies in Europe. Using a unique, highly cost efficient business model, the
management team guides the commercialization of world class life science
innovations, helping to shape the next generation Pharma industry. Since 2003,
Karolinska Development has built a portfolio of some 40 companies; among the
company's projects 12 compounds are undergoing clinical trials. The portfolio
contains a total of 21 potential first-in-class
products.www.karolinskadevelopment.com
About Electra-Box Diagnostica AB:
Electra-Box Diagnostica is a distribution company for products to research and
clinical laboratories in Sweden, Denmark, Norway, Finland and Baltic
countries.www.electrabox.com
[HUG#1440946]
Read as PDF:
http://hugin.info/143298/R/1440946/385287.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Athera Biotechnologies AB via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 27.08.2010 - 12:01 Uhr
Sprache: Deutsch
News-ID 40333
Anzahl Zeichen: 0
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 193 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Athera signs distribution agreement in Scandinavia"
steht unter der journalistisch-redaktionellen Verantwortung von
Athera Biotechnologies AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
